PLoS ONE · 2011 · 290 citations · 43 references
MedicineMolecular MedicineOncologyCancer ScreeningHepatologyMolecular DiagnosticsBiomarker ValidationCancer BiomarkersHepatocellular CarcinomaLiver CancerLiver DiseaseViral HepatitisChronic Hepatitis B - Associated CarcinomaCirculating Microrna DetectionCirculating MicrornasHepatic BiomarkersLiver BiomarkersMolecular Marker DetectionNovel Circulating BiomarkersTumor Marker Validation
BACKGROUND: MicroRNAs (miRNAs) have been shown to anticipate great cancer diagnostic potential. Recently, circulating miRNAs have been reported as promising biomarkers for various pathologic conditions. The objective of this study was to investigate the potential of serum miRNAs as novel biomarkers for hepatocellular carcinoma (HCC). METHODOLOGY/PRINCIPAL FINDINGS: This study was divided into four phases: (I) Ten candidate serum miRNAs were detected by using real-time RT-PCR, corresponding 10 HCC patients with chronic hepatitis B virus (HBV) infection and 10 age- and sex-matched healthy subjects. (II) Marker validation by real-time RT-PCR on HBV patients with (n = 48) or without HCC (n = 48), and healthy subjects (n = 24). (III) Marker detection by real-time RT-PCR in sera from another 14 HCC patients before and 1 month after surgical resection. (IV) We examined the correlation between the expressions of candidate serum miRNAs with clinical parameters of HCC patients. Although miR-222, miR-223 or miR-21 were significantly up- or down-regulated between HCC patients and healthy controls, no significant difference was observed in the levels of these miRNAs between HBV patients without and with HCC. MiR-122 in serum was significantly higher in HCC patients than healthy controls (p<0.001). More importantly, it was found that the levels of miR-122 were significantly reduced in the post-operative serum samples when compared to the pre-operative samples. Although serum miR-122 was also elevated in HBV patients with HCC comparing with those without HCC, the difference was at the border line (p = 0.043). CONCLUSIONS/SIGNIFICANCE: Our results suggest that serum miR-122 might serve as a novel and potential noninvasive biomarker for detection of HCC in healthy subjects, moreover, it might serve as a novel biomarker for liver injury but not specifically for detection of HCC in chronic HBV infection patients.
43
Ahmedin Jemal, Freddie Bray, Jacques Ferlay et al. · CA A Cancer Journal for Clinicians · 2011 · 55K citations · Full text
Global Cancer Statistics, 2002
Donald Maxwell Parkin, Freddie Bray, Jacques Ferlay et al. · CA A Cancer Journal for Clinicians · 2005 · 18.4K citations · Full text
MicroRNA expression profiles classify human cancers
Jun Lü, Gad Getz, Eric A. Miska et al. · Nature · 2005 · 9.6K citations
Transection of the oesophagus for bleeding oesophageal varices
R. N. H. Pugh, I M Murray-Lyon, J L Dawson et al. · British journal of surgery · 1973 · 8K citations